Imatinib is specific for the tyrosine kinase domain in ABL and BCR-ABL gene products, it has been reported that treatment with BCR-ABL inhibitors, significantly reduces the application of hematopoietic cell transplantation for treatment of CML [28]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.